PRognosis Evaluation using in-Depth immune phenotyping and metagenomic analysis In Colorectal cancer Therapy

• Conditions: C18; C19; C20; Malignant neoplasm of colon; Malignant neoplasm of rectosigmoid junction; Malignant neoplasm of rectum

• Registration Number: DRKS00026081
• Lead Sponsor: Klinikum der Universität München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

Adult patients
Patients capable of giving informed consent
Presence of a valid declaration of informed consent
Presence of a valid declaration of informed consent for participation in biobanking
Patients with colorectal carcinoma or screening colonoscopy (control group)

Exclusion Criteria

age younger than 18 years
no informed consent for participation of biobanking

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference in the differential abundance of the colonic mucosa of patients with CRC vs. healthy controls for evaluation as diagnostic biomarkers based on metagenomic analyzes (microbial pattern)